These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 2867196)

  • 1. A selective potentiation by naloxone of L-dopa but not atropine suppression of oxotremorine-induced tremor in mice.
    Quock RM; Lucas TS
    J Pharm Pharmacol; 1985 Sep; 37(9):673-4. PubMed ID: 2867196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potentiation by naloxone of the anti-oxotremorine effect of L-DOPA.
    Quock RM; Lucas TS
    Eur J Pharmacol; 1983 Nov; 95(3-4):193-8. PubMed ID: 6653670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Device for quantitating tremor activity in mice: antitremor activity of atropine versus soman- and oxotremorine-induced tremors.
    Clement JG; Dyck WR
    J Pharmacol Methods; 1989 Aug; 22(1):25-36. PubMed ID: 2770314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Abolition of oxotremorine effects by L-DOPA pretreatment.
    Korczyn AD; Eshel Y
    Neuropharmacology; 1979 Jul; 18(7):601-3. PubMed ID: 573869
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of L-5HTP on tremorine- or oxotremorine-induced tremor in mice and rats.
    Omori K; Kojima T
    Jpn J Pharmacol; 1973 Dec; 23(6):901-3. PubMed ID: 4274100
    [No Abstract]   [Full Text] [Related]  

  • 6. Further studies on the role of cholinergic mechanisms in the development of increased naloxone potency in mice.
    Wong CL; Bentley GA
    Eur J Pharmacol; 1979 Jun; 56(1-2):115-21. PubMed ID: 157281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Power spectral analysis of tremor induced by TRH and oxotremorine in mice].
    Koja T; Nomoto M; Shimizu T; Izumi K; Fukuda T
    Nihon Yakurigaku Zasshi; 1986 Aug; 88(2):159-65. PubMed ID: 3095204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cholinergic involvement in the modulation of oxotremorine-tremor in mice by propranolol.
    Alkondon M; Ray A; Sen P
    Arch Int Pharmacodyn Ther; 1985 Sep; 277(1):161-7. PubMed ID: 2865935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of the structural requirements for dopa potentiation and oxotremorine antagonism by L-prolyl-L-leucylglycinamide.
    Johnson RL; Smissman EE; Plotnikoff NP
    J Med Chem; 1978 Feb; 21(2):165-9. PubMed ID: 23433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Some observations on the effects of enantiomers of two benzomorphan narcotic antagonists and atropine on analgesia, tremor and hypothermia produced by oxotremorine.
    Ben-Sreti MM; Sewell RD; Upton N
    Arch Int Pharmacodyn Ther; 1982 Apr; 256(2):219-27. PubMed ID: 7103612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interactions between oxotremorine and inhibitors of cholinesterase enzymes.
    Cox B; Tha SJ
    J Pharm Pharmacol; 1973 Jul; 25(7):544-9. PubMed ID: 4147051
    [No Abstract]   [Full Text] [Related]  

  • 12. Oxotremorine-induced cholinergic syndrome: modifications by levodopa and/or oral cytidine diphosphocholine.
    Saligaut C; Daoust M; Chadelaud M; Moore N; Chretien P; Boismare F
    Methods Find Exp Clin Pharmacol; 1985 Jan; 7(1):5-8. PubMed ID: 3990445
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo antimuscarinic actions of the third generation antihistaminergic agent, desloratadine.
    Howell G; West L; Jenkins C; Lineberry B; Yokum D; Rockhold R
    BMC Pharmacol; 2005 Aug; 5():13. PubMed ID: 16109168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Central cholinergic-dopaminergic interaction in carbaryl-induced tremor.
    Ray SK; Poddar MK
    Eur J Pharmacol; 1985 Dec; 119(3):251-3. PubMed ID: 3937737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of atropine and dyflos on tremor and increase in whole brain acetylcholine produced by injection of oxotremorine in the rat.
    Cox B; Potkonjak D
    Br J Pharmacol; 1969 Mar; 35(3):521-9. PubMed ID: 5809741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of oxotremorine tremor and hypothermia by injections of drugs into the cerebral ventricles of the mouse.
    Doggett NS; O'Farrell SA
    Naunyn Schmiedebergs Arch Pharmacol; 1976 Aug; 294(2):149-55. PubMed ID: 1012335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The central and peripheral effectiveness of two oxotremorine-antagonists determined using oxotremorine-induced tremor and salivation.
    Eicholzer A; Ogren SO
    J Pharm Pharmacol; 1977 Oct; 29(10):609-11. PubMed ID: 21240
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonism of tremorine-induced tremor by serotoninergic agents in mice. Interactions with levodopa.
    Rodríguez R
    Life Sci I; 1972 Jun; 11(11):535-44. PubMed ID: 4540331
    [No Abstract]   [Full Text] [Related]  

  • 19. The pharmacology of N-carbamoyl-2-(2,6-dichlorophenyl)acetamidine hydrochloride (LON-954) a new tremorogenic agent.
    Coward DM; Doggett NS; Sayers AC
    Arzneimittelforschung; 1977; 27(12):2326-32. PubMed ID: 580044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of AIT-082, a purine derivative, on tremor induced by arecoline or oxotremorine in mice.
    Nannan G; Runmei Y; Fusheng L; Shoulan Z; Guangqing L
    Pharmacology; 2007; 80(1):21-6. PubMed ID: 17496436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.